LRRK2 and Parkinson disease: Thus, the investigation of these dopamine and striatal dysfunctions that characterize the prodromal PD in the mutant LRRK2 KI mouse provides the framework for implementing neuroprotective therapies and developing biomarkers to detect and monitor disease progression related to LRRK2 mutations.